Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Rare Gastrointestinal Diseases Treatment Market Size Forecast: How Large Could The Market Become By 2030?
The market for treating rare gastrointestinal diseases has experienced solid expansion in recent years, with projections indicating an increase from $1.45 billion in 2025 to $1.53 billion in 2026, representing a compound annual growth rate (CAGR) of 5.9%. This growth during the historical period has been driven by factors such as heightened awareness and identification of uncommon GI conditions, the proliferation of specialized gastroenterology clinics, the accessibility of immunosuppressive and anti-inflammatory medications, a surge in clinical research efforts, and advancements in diagnostic precision.
The market for treating rare gastrointestinal diseases is projected to experience robust expansion in the coming years. By 2030, it is anticipated to reach a value of $1.91 billion, reflecting a compound annual growth rate (CAGR) of 5.6%. This forecasted growth is driven by several key factors, including the accelerated development of orphan drugs, heightened investment in research dedicated to rare conditions, wider adoption of biologic therapies, the evolution of precision medicine strategies, and improved patient access to cutting-edge treatments. Among the prominent trends expected to shape this period are the growing embrace of targeted biologic therapies, an increased emphasis on individualized treatment regimens, broader utilization of sophisticated diagnostic tools, expanded implementation of enzyme replacement therapies, and deeper incorporation of digital patient monitoring systems.
Download A Free Sample Report For Comprehensive Market Insights:
Rare Gastrointestinal Diseases Treatment Market Development Factors: Which Trends Are Supporting Demand?
The increasing prevalence of diagnostic testing is anticipated to drive expansion within the rare gastrointestinal diseases treatment market going forward. Such tests are medical procedures utilized for detecting, diagnosing, or tracking diseases, conditions, or infections in patients, and their growing adoption is largely fueled by heightened awareness of the benefits of early disease identification, which facilitates prompt therapeutic actions and improved health results. By enabling early and accurate recognition of underlying disorders, diagnostic testing plays a crucial role in managing rare gastrointestinal diseases, assisting in the identification of specific disease mechanisms, supporting tailored therapeutic strategies, and enhancing patient outcomes through timely care. For example, data from December 2024 released by the National Health Service, a UK government body, shows that diagnostic tests by activity totaled 2,544,809 in 2024, up from 2,312,030 in 2023. As a result, this upward trend in diagnostic testing is fueling growth in the market for treating rare gastrointestinal diseases.
Rare Gastrointestinal Diseases Treatment Market Segment Performance And Strategic Opportunities
The rare gastrointestinal diseases treatment market covered in this report is segmented –
1) By Type: Drugs, Device
2) By Route Of Administration: Oral, Intravenous (IV) Or Injectable, Subcutaneous, Other Routes Of Administration
3) By Application: Eosinophilic Gastroenteritis, Hercksprung’s Disease, Chronic Intestinal Pseudo-Obstruction
4) By End User: Hospitals, Research Institutes, Other End Users
Subsegments:
1) By Drugs: Anti-Inflammatory Drugs, Immunosuppressive Agents, Biologic Therapies, Antibiotics, Proton Pump Inhibitors, Corticosteroids, Enzyme Replacement Therapies
2) By Devices: Endoscopic Devices, Diagnostic Imaging Systems, Surgical Instruments, Feeding Tubes, Stent Devices, Biopsy Devices
Rare Gastrointestinal Diseases Treatment Market Transformation Trends: Which Innovations Are Driving Change?
Key players in the rare gastrointestinal diseases treatment market are concentrating on creating novel therapies, including fully human monoclonal antibodies, to target disease mechanisms and enhance patient outcomes. These antibodies are laboratory-produced from entirely human proteins, designed to precisely bind to and modulate disease-causing molecules, thereby boosting treatment efficacy and minimizing adverse effects. For example, in August 2023, Regeneron Pharmaceuticals Inc., a biotechnology firm based in the United States, secured approval from the U.S. Food and Drug Administration (FDA) for Veopoz (pozelimab-bbfg) to treat CHAPLE disease, a rare and severe hereditary gastrointestinal condition. Veopoz functions as a fully human monoclonal antibody that targets complement factor C5, thereby regulating the hyperactive complement system responsible for protein leakage and gastrointestinal harm in CHAPLE patients. This specific mode of action tackles the root cause of the disorder, preventing debilitating symptoms and potentially fatal complications.
Rare Gastrointestinal Diseases Treatment Market Key Players: Which Companies Shape Industry Competition?
Major companies operating in the rare gastrointestinal diseases treatment market are Johnson & Johnson, Merck & Co. Inc., Pfizer Inc., Bayer AG, Sanofi S.A., Zealand Pharma A/S, Novartis AG, AstraZeneca plc, GlaxoSmithKline plc, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Ipsen S.A., PTC Therapeutics Inc., Ironwood Pharmaceuticals Inc., Mirum Pharmaceuticals Inc., Albireo Pharma Inc., Orphalan S.A., Ellodi Pharmaceuticals Inc.
Access The Complete Rare Gastrointestinal Diseases Treatment Market Report:
Rare Gastrointestinal Diseases Treatment Market Largest Region: Which Geography Holds The Highest Market Share?
North America was the largest region in the rare gastrointestinal diseases treatment market in 2025. The regions covered in the rare gastrointestinal diseases treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model